KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

NASDAQ:KRYS • US5011471027

275.64 USD
-0.72 (-0.26%)
At close: Feb 27, 2026
275.64 USD
0 (0%)
After Hours: 2/27/2026, 8:14:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 520 industry peers in the Biotechnology industry. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KRYS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • KRYS had positive earnings in the past year.
  • In the past year KRYS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: KRYS reported negative operating cash flow in multiple years.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • KRYS has a better Return On Assets (15.36%) than 95.98% of its industry peers.
  • With an excellent Return On Equity value of 16.80%, KRYS belongs to the best of the industry, outperforming 94.83% of the companies in the same industry.
  • KRYS's Return On Invested Capital of 10.34% is amongst the best of the industry. KRYS outperforms 94.44% of its industry peers.
Industry RankSector Rank
ROA 15.36%
ROE 16.8%
ROIC 10.34%
ROA(3y)8.38%
ROA(5y)-2.21%
ROE(3y)9.21%
ROE(5y)-2.18%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • KRYS has a Profit Margin of 52.64%. This is amongst the best in the industry. KRYS outperforms 98.47% of its industry peers.
  • The Operating Margin of KRYS (41.41%) is better than 98.66% of its industry peers.
  • Looking at the Gross Margin, with a value of 94.08%, KRYS belongs to the top of the industry, outperforming 94.64% of the companies in the same industry.
Industry RankSector Rank
OM 41.41%
PM (TTM) 52.64%
GM 94.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KRYS is still creating some value.
  • KRYS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, KRYS has more shares outstanding
  • There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 43.53 indicates that KRYS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 43.53, KRYS belongs to the top of the industry, outperforming 94.83% of the companies in the same industry.
  • KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 43.53
ROIC/WACC1.2
WACC8.61%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • KRYS has a Current Ratio of 9.95. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of KRYS (9.95) is better than 81.03% of its industry peers.
  • A Quick Ratio of 9.56 indicates that KRYS has no problem at all paying its short term obligations.
  • The Quick ratio of KRYS (9.56) is better than 80.27% of its industry peers.
Industry RankSector Rank
Current Ratio 9.95
Quick Ratio 9.56
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.10%, which is quite impressive.
  • KRYS shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.95%.
EPS 1Y (TTM)129.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.84%
Revenue 1Y (TTM)33.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.52%

3.2 Future

  • KRYS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.62% yearly.
  • The Revenue is expected to grow by 28.70% on average over the next years. This is a very strong growth
EPS Next Y21.58%
EPS Next 2Y22.05%
EPS Next 3Y36.11%
EPS Next 5Y9.62%
Revenue Next Year42.21%
Revenue Next 2Y38.45%
Revenue Next 3Y34.3%
Revenue Next 5Y28.7%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 40.24, the valuation of KRYS can be described as expensive.
  • KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 90.80% of the companies in the same industry.
  • KRYS is valuated rather expensively when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 33.10, which means the current valuation is very expensive for KRYS.
  • Based on the Price/Forward Earnings ratio, KRYS is valued cheaper than 91.38% of the companies in the same industry.
  • KRYS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 40.24
Fwd PE 33.1
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaply inside the industry as 91.57% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 92.91% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 42.31
EV/EBITDA 40.96
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates KRYS does not grow enough to justify the current Price/Earnings ratio.
  • KRYS has a very decent profitability rating, which may justify a higher PE ratio.
  • KRYS's earnings are expected to grow with 36.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.86
PEG (5Y)N/A
EPS Next 2Y22.05%
EPS Next 3Y36.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KRYS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KRYSTAL BIOTECH INC

NASDAQ:KRYS (2/27/2026, 8:14:59 PM)

After market: 275.64 0 (0%)

275.64

-0.72 (-0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners96.44%
Inst Owner Change-0.74%
Ins Owners11.65%
Ins Owner Change-1.42%
Market Cap7.99B
Revenue(TTM)389.13M
Net Income(TTM)204.83M
Analysts86.67
Price Target313.24 (13.64%)
Short Float %10.95%
Short Ratio9.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)79.28%
Min EPS beat(2)18.32%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)39.2%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)11.67%
EPS beat(12)5
Avg EPS beat(12)3.31%
EPS beat(16)8
Avg EPS beat(16)3.37%
Revenue beat(2)1
Avg Revenue beat(2)1.29%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)3
Avg Revenue beat(8)-1.04%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.05%
PT rev (3m)38.05%
EPS NQ rev (1m)-11.68%
EPS NQ rev (3m)-8.38%
EPS NY rev (1m)2.76%
EPS NY rev (3m)5.93%
Revenue NQ rev (1m)-3.67%
Revenue NQ rev (3m)-3.82%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-2.67%
Valuation
Industry RankSector Rank
PE 40.24
Fwd PE 33.1
P/S 20.54
P/FCF 42.31
P/OCF 39.8
P/B 6.55
P/tB 6.55
EV/EBITDA 40.96
EPS(TTM)6.85
EY2.49%
EPS(NY)8.33
Fwd EY3.02%
FCF(TTM)6.51
FCFY2.36%
OCF(TTM)6.93
OCFY2.51%
SpS13.42
BVpS42.05
TBVpS42.05
PEG (NY)1.86
PEG (5Y)N/A
Graham Number80.51
Profitability
Industry RankSector Rank
ROA 15.36%
ROE 16.8%
ROCE 13.09%
ROIC 10.34%
ROICexc 31.58%
ROICexgc 31.58%
OM 41.41%
PM (TTM) 52.64%
GM 94.08%
FCFM 48.55%
ROA(3y)8.38%
ROA(5y)-2.21%
ROE(3y)9.21%
ROE(5y)-2.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 208.79%
Cap/Sales 3.07%
Interest Coverage 250
Cash Conversion 120.39%
Profit Quality 92.23%
Current Ratio 9.95
Quick Ratio 9.56
Altman-Z 43.53
F-Score7
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)171.82%
Cap/Depr(5y)857.51%
Cap/Sales(3y)9.27%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.84%
EPS Next Y21.58%
EPS Next 2Y22.05%
EPS Next 3Y36.11%
EPS Next 5Y9.62%
Revenue 1Y (TTM)33.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.52%
Revenue Next Year42.21%
Revenue Next 2Y38.45%
Revenue Next 3Y34.3%
Revenue Next 5Y28.7%
EBIT growth 1Y56.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.89%
EBIT Next 3Y57.38%
EBIT Next 5YN/A
FCF growth 1Y58.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.75%
OCF growth 3YN/A
OCF growth 5YN/A

KRYSTAL BIOTECH INC / KRYS FAQ

Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?

ChartMill assigns a fundamental rating of 6 / 10 to KRYS.


What is the valuation status for KRYS stock?

ChartMill assigns a valuation rating of 6 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Fairly Valued.


What is the profitability of KRYS stock?

KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for KRYS stock?

The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 40.24 and the Price/Book (PB) ratio is 6.55.


What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?

The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.